Results 121 to 130 of about 33,325 (191)

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, Volume 66, Issue S2, Page S29-S44, September 2026.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Salutary roles of CD39 in transplantation

, 2007
Transplantation exposes vascularized grafts to several potential injuries, including ischemia-reperfusion injury and rejection. These processes are associated with, at least in part, extracellular nucleotide-triggered (type 2 purinergic receptor ...
SC Robson (14541245), K Enjyoji (13612147), TB Strom (14541332), KM Dwyer (14448135), S Crikis (13612123), PJ Cowan (14541248), AJF d'Apice (14541341), W Gao (7772054), S Deaglio (13612099)   +8 more
core  

Impact of cryopreservation on immune cell subset frequencies in human peripheral blood mononuclear cells following assessment of monoclonal antibodies to CD39 and P2X7. [PDF]

Purinergic Signal
Koning L, Splitt A, Brungs D, Carolan MG, Gandhidasan S, Sluyter R.   +5 more
europepmc   +1 more source

RanBPM associates with CD39 and modulates ecto-nucleotidase activity

, 2006
CD39/ecto-NTPDase 1 (nucleoside triphosphate diphosphohydrolase 1) is an ecto-nucleotidase that influences P2 receptor activation to regulate vascular and immune cell adhesion and signalling events pivotal in inflammation.
Y Wu (808222), SC Robson (14541245), A Usheva (13612159), KM Dwyer (14448135), X Sun (6794357), E Bianchi (13612156), E Kaczmarek (13612153)   +6 more
core  

Impaired regulation by purinergic signaling axis contributes to CD8+ T cell dysregulation in STAT3 gain of function. [PDF]

JCI Insight
Campos Duran JS, Knight MS, Sayed SU, Dalalo MC, Mauracher AA, Conrey P, Schultz AB, Hay CA, Lindell RB, Neale I, Yeakle K, Abrams ED, Schmitt EG, Thelin MA, Howard CA, Bluestein S, Seroogy CM, Pozos TC, Thatayatikom A, Lundgren IS, Gauthier A, Canna SW, Su HC, Keller MD, Delmonte OM, Forbes Satter LR, Holland SM, Bergerson JR, Leiding JW, Romberg N, Bailis W, Hunter CA, Freeman AF, Villarino AV, Anderson MS, Cooper MA, Vogel TP, Henrickson SE.   +37 more
europepmc   +1 more source

Adenosine signaling in tumor immune escape: metabolic checkpoints, myeloid suppression, and combination immunotherapy. [PDF]

Front Oncol
Li R, Li S, Zhang T.
europepmc   +1 more source

Quieting the carrier: Matching delivery to immunology in anti-inflammatory mRNA therapy. [PDF]

Mol Ther Nucleic Acids
Candiani G.
europepmc   +1 more source

Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39⁺CD8⁺ T cells highlights immunotherapy-resistant features in NSCLC. [PDF]

J Immunother Cancer
Wu J, Zhai J, Lv L, Zhang Y, Shen Y, Qu Q, Chen C.   +6 more
europepmc   +1 more source

CD39 EXPRESSION MODULATES ISCHEMIA INDUCED DIASTOLIC DYSFUNCTION

, 2012
CD39 EXPRESSION MODULATES ISCHEMIA INDUCED DIASTOLIC ...
Anthony JF d'Apice (14541305), Debra G Wheeler (13612282), Richard J Gumina (13355988), Sibel Gokce (19214131), Shouvik D Mahamud (13612690), Zhaobin Xu (381351), Karen M Dwyer (14541281), Simon C Robson (13355982), Peter J Cowan (13355985)   +8 more
core  

Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle-invasive bladder cancer. [PDF]

J Pathol Clin Res
Ledderose S, Schwenke J, Eismann L, Rodler S, Rudelius M, Ledderose C.   +5 more
europepmc   +1 more source